ImpediMed Valuation

Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IPD (A$0.07) is trading below our estimate of fair value (A$0.23)

Significantly Below Fair Value: IPD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPD?

Other financial metrics that can be useful for relative valuation.

IPD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.9x
Enterprise Value/EBITDA-5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IPD's PS Ratio compare to its peers?

The above table shows the PS ratio for IPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.9x
CYC Cyclopharm
6x31.7%AU$162.4m
OIL Optiscan Imaging
58.9xn/aAU$137.8m
AHC Austco Healthcare
1.5xn/aAU$66.7m
CMP Compumedics
1.1xn/aAU$56.7m
IPD ImpediMed
14.9x39.8%AU$149.7m

Price-To-Sales vs Peers: IPD is good value based on its Price-To-Sales Ratio (14.9x) compared to the peer average (18.2x).


Price to Earnings Ratio vs Industry

How does IPD's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (14.9x) compared to the Australian Medical Equipment industry average (4.6x).


Price to Sales Ratio vs Fair Ratio

What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.9x
Fair PS Ratio18.8x

Price-To-Sales vs Fair Ratio: IPD is good value based on its Price-To-Sales Ratio (14.9x) compared to the estimated Fair Price-To-Sales Ratio (18.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.074
AU$0.18
+136.9%
15.0%AU$0.20AU$0.14n/a4
Jun ’25AU$0.076
AU$0.18
+130.7%
15.0%AU$0.20AU$0.14n/a4
May ’25AU$0.079
AU$0.18
+121.9%
15.0%AU$0.20AU$0.14n/a4
Apr ’25AU$0.09
AU$0.18
+101.5%
16.2%AU$0.20AU$0.14n/a3
Mar ’25AU$0.091
AU$0.18
+99.3%
16.2%AU$0.20AU$0.14n/a3
Feb ’25AU$0.10
AU$0.22
+105.5%
16.2%AU$0.26AU$0.18n/a3
Jan ’25AU$0.14
AU$0.22
+51.7%
15.5%AU$0.26AU$0.18n/a3
Dec ’24AU$0.14
AU$0.22
+59.9%
15.5%AU$0.26AU$0.18n/a3
Nov ’24AU$0.10
AU$0.27
+159.2%
30.6%AU$0.39AU$0.21n/a3
Oct ’24AU$0.17
AU$0.23
+32.9%
52.4%AU$0.39AU$0.06n/a4
Sep ’24AU$0.17
AU$0.23
+32.9%
52.4%AU$0.39AU$0.06n/a4
Aug ’24AU$0.20
AU$0.24
+21.1%
49.6%AU$0.39AU$0.06n/a4
Jul ’24AU$0.18
AU$0.17
-8.3%
37.0%AU$0.21AU$0.06n/a4
Jun ’24AU$0.14
AU$0.17
+18.0%
37.0%AU$0.21AU$0.06AU$0.0764
May ’24AU$0.17
AU$0.16
-1.5%
38.3%AU$0.23AU$0.06AU$0.0794
Apr ’24AU$0.10
AU$0.18
+83.4%
19.6%AU$0.23AU$0.14AU$0.093
Mar ’24AU$0.059
AU$0.15
+147.4%
47.1%AU$0.23AU$0.04AU$0.0914
Feb ’24AU$0.06
AU$0.17
+175.1%
56.4%AU$0.30AU$0.04AU$0.104
Jan ’24AU$0.074
AU$0.18
+141.6%
51.7%AU$0.30AU$0.04AU$0.144
Dec ’23AU$0.091
AU$0.18
+96.4%
51.7%AU$0.30AU$0.04AU$0.144
Nov ’23AU$0.091
AU$0.18
+96.4%
51.7%AU$0.30AU$0.04AU$0.104
Oct ’23AU$0.063
AU$0.18
+183.8%
51.7%AU$0.30AU$0.04AU$0.174
Sep ’23AU$0.065
AU$0.18
+175.0%
51.7%AU$0.30AU$0.04AU$0.174
Aug ’23AU$0.069
AU$0.30
+338.1%
29.0%AU$0.41AU$0.19AU$0.203
Jul ’23AU$0.06
AU$0.32
+432.1%
21.3%AU$0.41AU$0.25AU$0.183
Jun ’23AU$0.084
AU$0.32
+280.1%
21.3%AU$0.41AU$0.25AU$0.143

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.